Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome

Pediatric Nephrology

Volumn 27, Issue 9, 2012, Pages 1511-1517

  Chiou, Yee Hsuan ^a   Wang, Lin Yu ^b   Wang, Tzu Hui ^a,b   Huang, Shiao Ping ^b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b FOOYIN UNIVERSITY   (Taiwan)

Author keywords

ABCB1; CYP3A5; Idiopathic nephrotic syndrome; Polymorphism; Steroid

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE;

ARTICLE; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TREND STUDY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DRUG RESISTANCE; FEMALE; GENOTYPE; GLUCOCORTICOIDS; HUMANS; MALE; NEPHROTIC SYNDROME; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PREDNISOLONE;

EID: 84864466340     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2182-0     Document Type: Article

References (39)

1. International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98:561-564
2. McBryde KD, Kershaw DB, Smoyer WE (2001) Pediatric steroidresistant nephrotic syndrome. Curr Probl Pediatr Adolesc Health Care 31:280-307
3. Tune BM, Mendoza SA (1997) Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 8:824-832 (Pubitemid 27493599)
4. Subramanya A, Houghton D, Watnick S (2005) Steroid-responsive idiopathic glomerular capillary endotheliosis: case report and literature review. Am J Kidney Dis 45:1090-1095 (Pubitemid 40806523)
5. Schwab M, Eichelbaum M, Fromm MF (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307 (Pubitemid 37372643)
6. Stachowski J, Zanker CB, Runowski D, Zaniew M, Peszko A, Medynska A, Zwolinska D, Rogowska-Kalisz A, Hyla-Klekot L, Szprygner K, Weglarska J, Sieniawska M, Musial W, Maciejewski J, Baldamus CA (2000) Resistance to therapy in primary nephrotic syndrome: effect of MDR1 gene activity. Pol Merkuriusz Lek 8:218-221
7. Sakaeda T, Nakamura T, Okumura K (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397-410 (Pubitemid 36857176)
8. Eichelbaum M, Fromm MF, Schwab M (2004) Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26:180-185 (Pubitemid 38501215)
9. Gumus-Akay G, Rustemoglu A, Karadag A, Sunguroglu A (2008) Genotype and allele frequencies of MDR1 gene C1236T polymorphism in a Turkish population. Genet Mol Res 7:1193-1199
10. Xu P, Jiang ZP, Zhang BK, Tu JY, Li HD (2008) Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology 82:221-227
11. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42 (Pubitemid 26096749)
12. Hakkola J, Pelkonen O, Pasanen M, Raunio H (1998) Xenobioticmetabolizing cytochrome P450 enzymes in the human fetoplacental unit: role in intrauterine toxicity. Crit Rev Toxicol 28:35-72 (Pubitemid 28100181)
13. Thummel KE, Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430 (Pubitemid 28231501)
14. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294 (Pubitemid 35284253)
15. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172 (Pubitemid 34680528)
16. Finta C, Zaphiropoulos PG (2000) The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260:13-23 (Pubitemid 32008496)
17. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111-121 (Pubitemid 32216122)
18. Beaune PH, Kremers PG, Kaminsky LS, De Graeve J, Albert A, Guengerich FP (1986) Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab Dispos 14:437-442 (Pubitemid 16075245)
19. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036 (Pubitemid 18075638)
20. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388-10395 (Pubitemid 19161599)
21. Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K, Watlington CO (1992) Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 294:206-214
22. Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, Raunio H (1997) Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 16:242-249 (Pubitemid 127497446)
23. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391 (Pubitemid 32268418)
24. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235 (Pubitemid 37339651)
25. Zheng H,Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 andMDR1 gene polymorphisms. Am J Transplant 3:477-483 (Pubitemid 36560101)
26. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199 (Pubitemid 32777772)
27. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693-704 (Pubitemid 41345321)
28. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528 (Pubitemid 46175758)
29. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmoller J, Cascorbi I, Roots I (2002) Modulation of steady state kinetics of digoxin by haplotypes of the Pglycoprotein MDR1 gene. Clin Pharmacol Ther 72:574-594
30. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, SchlageterMH, Cassinat B, Beaune P, Legendre C, Thervet E (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14:1889-1896 (Pubitemid 36750485)
31. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schakel U, Ehninger G, Schaich M (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955-4962 (Pubitemid 34984419)
32. Wasilewska A, Zalewski G, Chyczewski L, Zoch-Zwierz W (2007) MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol 22:44-51 (Pubitemid 46138359)
33. Jafar T, Prasad N, Agarwal V, Mahdi A, Gupta A, Sharma RK, Negi MP, Agrawal S (2011) MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 26:3968-3974
34. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:437-450 (Pubitemid 34913526)
35. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P (1992) Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 41:1047-1055 (Pubitemid 23026103)
36. Tada H, Tsuchida N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T (2005) Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37:1730-1732 (Pubitemid 40790812)
37. Ferraris JR, Argibay PF, Costa L, Jimenez G, Coccia PA, Ghezzi LF, Ferraris V, Belloso WH, Redal MA, Larriba JM (2011) Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Pediatr Transplant 15:525-532
38. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Habuchi T, Suzuki T (2008) Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 73:1052-1059
39. Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590 (Pubitemid 32448326)